Crystalline form of reverse transcriptase inhibitor

Crystalline form of reverse transcriptase inhibitor. The retrovirus designated human immunodeficiency virus (HIV), particularly the strains known as HIV type-1 (HIV-I) and type-2 (HIV-2), have been etiologically linked to the immunosuppressive disease known as acquired immunodeficiency syndrome (AID...

Full description

Saved in:
Bibliographic Details
Main Author MAGUIRE COURTNEY K
Format Patent
LanguageChinese
English
Published 26.02.2019
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:Crystalline form of reverse transcriptase inhibitor. The retrovirus designated human immunodeficiency virus (HIV), particularly the strains known as HIV type-1 (HIV-I) and type-2 (HIV-2), have been etiologically linked to the immunosuppressive disease known as acquired immunodeficiency syndrome (AIDS). HIV seropositive individuals are initially asymptomatic but typically develop AIDS related complex (ARC) followed by AIDS. Affected individuals exhibit severe immunosuppression which makes them highly susceptible to debilitating and ultimately fatal opportunistic infections. The invention is directed to a novel crystalline form of the RT inhibitor 3-chloro-5-({1-[( 4-methyl-5 -oxo-4,5 -dihydro-1H -1,2, 4-triazol-3 -yl)methyl]-2-oxo-4-( trifluoromethy 1 )-1,2-dihydropyridin-3 -yl) oxy )benzonitrile used in the treatment HIV infection and AIDS. 逆转录酶抑制剂的晶型。命名为人免疫缺陷病毒(HIV)的逆转录病毒，特别地称为HIV类型-1(HIV-1)和类型-2(HIV-2)的菌株，病因学上与称为获得性免疫缺陷综合征(AIDS)的免疫抑制疾病有关。HIV血清反应阳性个体最初无症状但通常形成AIDS相关综合征(ARC)随后是AIDS。受感染的个体表现严重的免疫抑制，其使他们非常易感衰弱并
Bibliography:Application Number: CN201811295039